MedPath

Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women

Phase 3
Completed
Conditions
HIV Infections
Interventions
Dietary Supplement: Multivitamins-Single RDA
Dietary Supplement: Multivitamins-Multiples of RDA
Registration Number
NCT00197678
Lead Sponsor
Harvard School of Public Health (HSPH)
Brief Summary

The purpose of this study is to examine effects of daily administration of multivitamin supplements at doses resembling the Recommended Dietary Allowance (RDA) during pregnancy to HIV positive women decreases the risks of low birth weight (\<2500 g), and pre-term birth (\< 37 weeks gestation), compared to multivitamin supplements at doses above the RDA.

Detailed Description

This is a randomized clinical trial conducted to examine effects of daily administration of multivitamin supplements at doses resembling the Recommended Dietary Allowance (RDA) during pregnancy to HIV positive women decreases the risks of low birth weight (\<2500 g), and pre-term birth (\< 37 weeks gestation), compared to multivitamin supplements at doses above the RDA. All women receive standard prenatal care, including nevirapine for the prevention of mother-to-child transmission of HIV.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
1141
Inclusion Criteria
  • HIV-positive pregnant women who are between 12 and 27 weeks gestation who intend to stay in Dar es Salaam until delivery.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Multivitamins-Single RDAMultivitamins-Single RDAMultivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
Multivitamins-Multiples of RDAMultivitamins-Multiples of RDAMultivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
Primary Outcome Measures
NameTimeMethod
Low birthweight (< 2500 g)Delivery
Pre-term birth (< 36 weeks gestation)Monthly until the 32nd week of pregnancy, once every 2 weeks from 32nd to 36th week
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Harvard School of Public Health

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath